SlideShare a Scribd company logo
Dr. Md. Ashraful Alam
Assistant Professor
Department of Nephrology
Enam Medical College and Hospital
Among anti-diabetic drugs, two group of drugs are considered
to have renoprotective action.
> SGLT-2i
> GLP-1RA
Mechanism of Kidney protection by
SGLT-2i
 Tubuloglomerular Feedback and Glomerular Hemodynamics :
Tubular workload and Hypoxia
Functional recovery of tubulointerstitial fibroblasts with SGLT2 inhibitor therapy (reverse remodeling). SGLT2 inhibitor
therapy suppresses oxygen consumption by the proximal tubules and improves tubulointerstitial hypoxia.
 Diuresis and Natriuresis
Anti-inflammatory Pathway
 SGLT-2i reduce levels of nuclear factor kB (NFkB),IL-6,
Monocyte chemoattractant protein 1 (MCP-1), and other factors
implicated in inflammation and tissue fibrosis in experimental
models of diabetes.
 Hyperuricemia may induce kidney inflammation and has been
reported to be a risk factor for incident DKD in T2DM and SGLT-2i
causes uricosuria.
GLP-1RA
Dose adjustment of SGLT-2i and GLP-
1RA in renal failure patients :
For SGLT-2i
When eGFR >30, no dose adjustment required.
When eGFR <30, contraindicated.
 It is reasonable to withhold SGLT2i during times of prolonged fasting,
surgery, or critical medical illness (when patients may be at greater
risk for ketosis).
 A reversible decrease in the eGFR with commencement of SGLT2i
treatment may occur and is generally not an indication to discontinue
therapy.
For GLP-1RA : (According to ADA guideline)
> No dose adjustment for dulaglutide, liraglutide and semaglutide .
> When eGFR < 30, avoid exenatide, lixisenatide.
GLP-1RA dose (According to KDIGO)
Which one has more Renoprotective Effect ?
(SGLT-2i or GLP-1RA)
 Although no trial has directly compared SGLT-2i with GLP-1RA, a
meta-analysis of 8 cardiovascular trials found a 38% and 18% lower
risk of new-onset UACR >300mg/g, doubling of S. creatinine, a
>40% decline in eGFR, kidney failure with replacement therapy or
death from kidney diseases for SGLT-2i and GLP-1RA, respectively.
 Thus, SGLT-2i appears to be more effective in slowing kidney
disease progression and should be considered before GLP-1RA.
Thank You

More Related Content

What's hot

Empagliflozin, cardiovascular outcomes, and mortality in type 2 DM
Empagliflozin, cardiovascular outcomes, and mortality in type 2 DMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 DM
Empagliflozin, cardiovascular outcomes, and mortality in type 2 DM
Anirudhya J
 
The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Con...
The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Con...The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Con...
The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Con...
PVI, PeerView Institute for Medical Education
 
Sodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitorsSodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitors
Moh'd sharshir
 
SGLT2i
SGLT2iSGLT2i
SGLT2i
dibufolio
 
Safety and tolerability of Empagliflozin
Safety and tolerability of EmpagliflozinSafety and tolerability of Empagliflozin
Safety and tolerability of Empagliflozin
Anwer Ghani
 
Sglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic control
Sglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic controlSglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic control
Sglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic control
DrSuman Roy
 
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosi...
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosi...Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosi...
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosi...
OlgaGoryacheva4
 
Anti-Diabetics For Cardiac Patients The Proper Selection
Anti-Diabetics For Cardiac Patients The Proper SelectionAnti-Diabetics For Cardiac Patients The Proper Selection
Anti-Diabetics For Cardiac Patients The Proper Selection
magdy elmasry
 
Pores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyPores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapy
Osama Almaraghi
 
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada SelimSGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
SGLT2 inhibitors in Diabetic Kidney Disease
SGLT2 inhibitors in Diabetic Kidney DiseaseSGLT2 inhibitors in Diabetic Kidney Disease
SGLT2 inhibitors in Diabetic Kidney Disease
Christos Argyropoulos
 
Sglt2 inhibitors past present and future
Sglt2 inhibitors past present and futureSglt2 inhibitors past present and future
Sglt2 inhibitors past present and future
Priyanka Thakur
 
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Dr Nick
 
Canagliflozin
Canagliflozin Canagliflozin
Canagliflozin
Saurabh Gupta
 
Jardiance- PresentationCopy
Jardiance- PresentationCopyJardiance- PresentationCopy
Jardiance- PresentationCopydannbetts
 
LEADER trial- Liraglutide - Journal club
LEADER trial- Liraglutide - Journal clubLEADER trial- Liraglutide - Journal club
LEADER trial- Liraglutide - Journal club
Simna Abdul Salam
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsPHAM HUU THAI
 
An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Dise...
An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Dise...An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Dise...
An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Dise...
PVI, PeerView Institute for Medical Education
 
Empagliflozin
EmpagliflozinEmpagliflozin
Empagliflozin
Viraj Shinde
 
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
Naina Mohamed, PhD
 

What's hot (20)

Empagliflozin, cardiovascular outcomes, and mortality in type 2 DM
Empagliflozin, cardiovascular outcomes, and mortality in type 2 DMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 DM
Empagliflozin, cardiovascular outcomes, and mortality in type 2 DM
 
The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Con...
The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Con...The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Con...
The Role of SGLT2 Inhibitors in Type 2 Diabetes: CV, Metabolic, and Renal Con...
 
Sodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitorsSodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitors
 
SGLT2i
SGLT2iSGLT2i
SGLT2i
 
Safety and tolerability of Empagliflozin
Safety and tolerability of EmpagliflozinSafety and tolerability of Empagliflozin
Safety and tolerability of Empagliflozin
 
Sglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic control
Sglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic controlSglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic control
Sglt2i Empagliflogin canagliflogin dapagliflogin- beyond glycemic control
 
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosi...
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosi...Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosi...
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosi...
 
Anti-Diabetics For Cardiac Patients The Proper Selection
Anti-Diabetics For Cardiac Patients The Proper SelectionAnti-Diabetics For Cardiac Patients The Proper Selection
Anti-Diabetics For Cardiac Patients The Proper Selection
 
Pores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyPores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapy
 
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada SelimSGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
SGLT2 Inhibitors in Diabetes Management by Dr Shahjada Selim
 
SGLT2 inhibitors in Diabetic Kidney Disease
SGLT2 inhibitors in Diabetic Kidney DiseaseSGLT2 inhibitors in Diabetic Kidney Disease
SGLT2 inhibitors in Diabetic Kidney Disease
 
Sglt2 inhibitors past present and future
Sglt2 inhibitors past present and futureSglt2 inhibitors past present and future
Sglt2 inhibitors past present and future
 
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
Journal- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fr...
 
Canagliflozin
Canagliflozin Canagliflozin
Canagliflozin
 
Jardiance- PresentationCopy
Jardiance- PresentationCopyJardiance- PresentationCopy
Jardiance- PresentationCopy
 
LEADER trial- Liraglutide - Journal club
LEADER trial- Liraglutide - Journal clubLEADER trial- Liraglutide - Journal club
LEADER trial- Liraglutide - Journal club
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
 
An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Dise...
An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Dise...An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Dise...
An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Dise...
 
Empagliflozin
EmpagliflozinEmpagliflozin
Empagliflozin
 
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
 

Similar to Renoprotective anti diabetic drugs

Sglt2 across the_spectrum_of_kidney_diseases
Sglt2 across the_spectrum_of_kidney_diseasesSglt2 across the_spectrum_of_kidney_diseases
Sglt2 across the_spectrum_of_kidney_diseases
Christos Argyropoulos
 
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptxsodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
LawanYarimaMasaba
 
Dapa ckd journal club
Dapa ckd journal clubDapa ckd journal club
Dapa ckd journal club
Priyanka Thakur
 
Dapagliflozin in Clinical Trial212.pptx
Dapagliflozin in Clinical Trial212.pptxDapagliflozin in Clinical Trial212.pptx
Dapagliflozin in Clinical Trial212.pptx
AliShahen2
 
00. ppt on renal benefit of empagliflozin.pptx
00. ppt on renal benefit of empagliflozin.pptx00. ppt on renal benefit of empagliflozin.pptx
00. ppt on renal benefit of empagliflozin.pptx
FatemaBegum22
 
Newer OHA and insulin
Newer OHA and insulinNewer OHA and insulin
Newer OHA and insulin
NamrataRaja1
 
Do T2DM drugs have CV benefit for Type 1 Diabetes ?
Do T2DM drugs have CV benefit for Type 1 Diabetes ?Do T2DM drugs have CV benefit for Type 1 Diabetes ?
Do T2DM drugs have CV benefit for Type 1 Diabetes ?
magdy elmasry
 
SGLT 2 inhibitors
SGLT 2 inhibitorsSGLT 2 inhibitors
SGLT 2 inhibitors
Naveen Kumar
 
3. Dapagliflozin.pptx
3. Dapagliflozin.pptx3. Dapagliflozin.pptx
3. Dapagliflozin.pptx
PaNkajGupTa467037
 
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert june 2022.pptx
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert  june 2022.pptxSGLT2 HF CKD Presentation NYSCHP Maya Chilbert  june 2022.pptx
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert june 2022.pptx
AdelSALLAM4
 
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic po...
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic po...GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic po...
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic po...
OlgaGoryacheva4
 
SGLT-2
SGLT-2 SGLT-2
SGLT-2
Anirudh Allam
 
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert.pdf
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert.pdfSGLT2 HF CKD Presentation NYSCHP Maya Chilbert.pdf
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert.pdf
ParikshitMishra15
 
ERLI_Product Presentation_without Video.pptx
ERLI_Product Presentation_without Video.pptxERLI_Product Presentation_without Video.pptx
ERLI_Product Presentation_without Video.pptx
riyankhattak
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
magdy elmasry
 
Journal dapagliflozin dapahf trial
Journal dapagliflozin   dapahf trialJournal dapagliflozin   dapahf trial
Journal dapagliflozin dapahf trial
Priyanka Thakur
 
Diabetic Kidney Disease
Diabetic Kidney DiseaseDiabetic Kidney Disease
Diabetic Kidney Disease
drsanjaymaitra
 
Dm and kidney August 23 2019
Dm and kidney August 23 2019Dm and kidney August 23 2019
Dm and kidney August 23 2019
Ala Ali
 
SGLT2 INHIBITORS IN NEPHROLOGY.pptx
SGLT2 INHIBITORS IN NEPHROLOGY.pptxSGLT2 INHIBITORS IN NEPHROLOGY.pptx
SGLT2 INHIBITORS IN NEPHROLOGY.pptx
Vishrut Khullar
 

Similar to Renoprotective anti diabetic drugs (20)

Sglt2 across the_spectrum_of_kidney_diseases
Sglt2 across the_spectrum_of_kidney_diseasesSglt2 across the_spectrum_of_kidney_diseases
Sglt2 across the_spectrum_of_kidney_diseases
 
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptxsodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
sodium Glucose co transporter 2 inhibitors GLIFLOZINS .pptx
 
Dapa ckd journal club
Dapa ckd journal clubDapa ckd journal club
Dapa ckd journal club
 
Dapagliflozin in Clinical Trial212.pptx
Dapagliflozin in Clinical Trial212.pptxDapagliflozin in Clinical Trial212.pptx
Dapagliflozin in Clinical Trial212.pptx
 
00. ppt on renal benefit of empagliflozin.pptx
00. ppt on renal benefit of empagliflozin.pptx00. ppt on renal benefit of empagliflozin.pptx
00. ppt on renal benefit of empagliflozin.pptx
 
Newer OHA and insulin
Newer OHA and insulinNewer OHA and insulin
Newer OHA and insulin
 
Do T2DM drugs have CV benefit for Type 1 Diabetes ?
Do T2DM drugs have CV benefit for Type 1 Diabetes ?Do T2DM drugs have CV benefit for Type 1 Diabetes ?
Do T2DM drugs have CV benefit for Type 1 Diabetes ?
 
SGLT 2 inhibitors
SGLT 2 inhibitorsSGLT 2 inhibitors
SGLT 2 inhibitors
 
3. Dapagliflozin.pptx
3. Dapagliflozin.pptx3. Dapagliflozin.pptx
3. Dapagliflozin.pptx
 
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert june 2022.pptx
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert  june 2022.pptxSGLT2 HF CKD Presentation NYSCHP Maya Chilbert  june 2022.pptx
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert june 2022.pptx
 
glyxambi
glyxambiglyxambi
glyxambi
 
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic po...
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic po...GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic po...
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic po...
 
SGLT-2
SGLT-2 SGLT-2
SGLT-2
 
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert.pdf
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert.pdfSGLT2 HF CKD Presentation NYSCHP Maya Chilbert.pdf
SGLT2 HF CKD Presentation NYSCHP Maya Chilbert.pdf
 
ERLI_Product Presentation_without Video.pptx
ERLI_Product Presentation_without Video.pptxERLI_Product Presentation_without Video.pptx
ERLI_Product Presentation_without Video.pptx
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
 
Journal dapagliflozin dapahf trial
Journal dapagliflozin   dapahf trialJournal dapagliflozin   dapahf trial
Journal dapagliflozin dapahf trial
 
Diabetic Kidney Disease
Diabetic Kidney DiseaseDiabetic Kidney Disease
Diabetic Kidney Disease
 
Dm and kidney August 23 2019
Dm and kidney August 23 2019Dm and kidney August 23 2019
Dm and kidney August 23 2019
 
SGLT2 INHIBITORS IN NEPHROLOGY.pptx
SGLT2 INHIBITORS IN NEPHROLOGY.pptxSGLT2 INHIBITORS IN NEPHROLOGY.pptx
SGLT2 INHIBITORS IN NEPHROLOGY.pptx
 

Recently uploaded

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
DR SETH JOTHAM
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 

Recently uploaded (20)

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 

Renoprotective anti diabetic drugs

  • 1. Dr. Md. Ashraful Alam Assistant Professor Department of Nephrology Enam Medical College and Hospital
  • 2. Among anti-diabetic drugs, two group of drugs are considered to have renoprotective action. > SGLT-2i > GLP-1RA
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. Mechanism of Kidney protection by SGLT-2i
  • 10.  Tubuloglomerular Feedback and Glomerular Hemodynamics :
  • 11. Tubular workload and Hypoxia Functional recovery of tubulointerstitial fibroblasts with SGLT2 inhibitor therapy (reverse remodeling). SGLT2 inhibitor therapy suppresses oxygen consumption by the proximal tubules and improves tubulointerstitial hypoxia.
  • 12.  Diuresis and Natriuresis
  • 13. Anti-inflammatory Pathway  SGLT-2i reduce levels of nuclear factor kB (NFkB),IL-6, Monocyte chemoattractant protein 1 (MCP-1), and other factors implicated in inflammation and tissue fibrosis in experimental models of diabetes.  Hyperuricemia may induce kidney inflammation and has been reported to be a risk factor for incident DKD in T2DM and SGLT-2i causes uricosuria.
  • 15.
  • 16. Dose adjustment of SGLT-2i and GLP- 1RA in renal failure patients : For SGLT-2i When eGFR >30, no dose adjustment required. When eGFR <30, contraindicated.  It is reasonable to withhold SGLT2i during times of prolonged fasting, surgery, or critical medical illness (when patients may be at greater risk for ketosis).  A reversible decrease in the eGFR with commencement of SGLT2i treatment may occur and is generally not an indication to discontinue therapy.
  • 17. For GLP-1RA : (According to ADA guideline) > No dose adjustment for dulaglutide, liraglutide and semaglutide . > When eGFR < 30, avoid exenatide, lixisenatide.
  • 19. Which one has more Renoprotective Effect ? (SGLT-2i or GLP-1RA)  Although no trial has directly compared SGLT-2i with GLP-1RA, a meta-analysis of 8 cardiovascular trials found a 38% and 18% lower risk of new-onset UACR >300mg/g, doubling of S. creatinine, a >40% decline in eGFR, kidney failure with replacement therapy or death from kidney diseases for SGLT-2i and GLP-1RA, respectively.  Thus, SGLT-2i appears to be more effective in slowing kidney disease progression and should be considered before GLP-1RA.